ACPU
ESPR icon

Arrowgrass Capital Partners (US)’s Esperion Therapeutics ESPR Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-35,000
Closed -$2.86M – 477
2015
Q2 		$2.86M Buy
+35,000
New +$3.43M 0.04% 289

Other funds holding ESPR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Pentwater Capital Management
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BB Biotech
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Discovery Capital Management
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s ESPR Position: Q3 2015 in Review

Arrowgrass Capital Partners (US) sold out of Esperion Therapeutics (ESPR) in Q3 2015, closing a stake of 35,000 shares — an estimated $2.86M sold.

Arrowgrass Capital Partners (US) first reported a position in ESPR in Q2 2015 and held it in 1 quarter. The position peaked at $2.86M in Q2 2015. 121 funds tracked by Wall St. Rank hold ESPR as of Q3 2015.

  • Arrowgrass Capital Partners (US) reported no remaining Esperion Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Arrowgrass Capital Partners (US) sold 35,000 Esperion Therapeutics shares in Q3 2015, an estimated $2.86M.
  • Arrowgrass Capital Partners (US) first reported a position in Esperion Therapeutics in Q2 2015 and held it in 1 quarter.
  • Arrowgrass Capital Partners (US)'s Esperion Therapeutics position peaked at $2.86M in Q2 2015.
  • 121 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q3 2015, filed 16 Nov 2015.